{"filings":[{"id":92099,"accession_number":"0001628280-26-029125","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).","Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.","Reaffirms FY 2026 guidance: revenue $91M-$96M; GAAP EPS $1.90-$2.05; non-GAAP EPS $2.06-$2.21.","Launched next-gen 3870 MRI-compatible IV infusion pump; early orders strong; Q2 shipments expected.","Operating cash flow $8.3M, up 93% YoY; gross margin improved to 77% from 76%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":21979000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102661,"accession_number":"0001104659-26-012356","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q4 revenue $22.7M, EPS $0.50; raises dividend to $0.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $22.7M (+17% YoY); GAAP diluted EPS $0.50 (+25%), non-GAAP $0.54 (+23%).","Full year 2025 revenue $83.8M (+14% YoY); GAAP diluted EPS $1.75 (+17%), non-GAAP $1.93 (+16%).","Quarterly dividend raised 18% to $0.20/share from $0.17, payable March 6, 2026 to holders of record Feb 23.","FY2026 guidance: revenue $91-96M, GAAP EPS $1.90-2.05, non-GAAP EPS $2.06-2.21.","Initial 3870 next-gen MRI pump shipped in Q4; full rollout begins Q1 2026 with meaningful H2 revenue contribution."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":83814000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118894,"accession_number":"0001104659-25-119090","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRadimed declares special cash dividend of $0.50 per share","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special dividend of $0.50 per share payable Dec 30, 2025 to holders of record Dec 17, 2025.","Company cites $56.5M cash as of Q3 2025, driven by 17 straight quarters of record revenue.","CEO Roger Susi says board chose to return excess cash rather than hold beyond operational needs.","Dividend complements regular quarterly program; future declarations remain at board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118893,"accession_number":"0001104659-25-105298","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).","Full-year 2025 guidance raised: revenue $82.5M-$83.5M, GAAP EPS $1.68-$1.72, non-GAAP EPS $1.84-$1.88.","Declares quarterly dividend of $0.17/share, payable Nov 25, 2025, record date Nov 14, 2025.","Next-generation 3870 MRI-compatible IV pump on track for limited commercial shipments Dec 2025, full rollout Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":61122101.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135440,"accession_number":"0001558370-25-011834","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Iradimed appoints Masimo founder Joe Kiani to board; Anthony Vuoto retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Vuoto retired as director effective Aug 27, 2025; no disagreement with the company.","Joe Kiani, founder of Masimo and CEO of Willow Laboratories, appointed director effective Sep 2, 2025.","Kiani will serve on the Audit Committee and chair the Compensation Committee.","Board size remains at five directors after the transition.","Kiani receives standard non-employee director compensation as disclosed in the 2025 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135439,"accession_number":"0001558370-25-009933","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).","Declares regular quarterly cash dividend of $0.17 per share, payable Aug 28, 2025.","FY2025 revenue guidance raised to $80-82.5M; GAAP EPS to $1.60-1.70; non-GAAP EPS to $1.76-1.86.","Gross profit margin held at 78%; record backlog for pump and monitor products as of June 30, 2025.","Q3 2025 guidance: revenue $20.5-20.9M, GAAP EPS $0.41-0.45, non-GAAP EPS $0.45-0.49."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":39920037.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152428,"accession_number":"0001558370-25-008791","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iradimed shareholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Roger Susi (8.85M for), Monty Allen (9.54M), Anthony Vuoto (10.76M), Hilda Scharen-Guivel (10.80M), James Hawkins (8.38M).","Ratification of RSM US LLP as auditor for FY2025: 11,775,729 for, 10,385 against, 1,399 abstentions.","Advisory say-on-pay resolution approved: 10,777,171 for, 286,889 against, 13,963 abstentions, 709,490 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152427,"accession_number":"0001558370-25-008245","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRadimed receives FDA 510(k) clearance for next-gen MRidium 3870 infusion pump","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance on May 29, 2025 for the MRidium 3870 IV Infusion Pump System.","Company remains the world's only supplier of non-magnetic MRI infusion pump devices (first device in 2005).","New pump features enhanced touchscreen UI, advanced safety, drug library, and four-channel capability.","Strategic rollout begins with initial units in Q4 2025; full commercial distribution ramps through 2026.","CEO Roger Susi says clearance is a milestone from FDA collaboration on evolving regulatory requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152426,"accession_number":"0001558370-25-006220","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iradimed Q1 record revenue $19.5M (+11% YoY); EPS $0.37 GAAP, $0.42 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue of $19.5M, up 11% YoY from $17.6M; GAAP diluted EPS $0.37 (+16% YoY).","Non-GAAP diluted EPS $0.42 (+17% YoY); excludes $0.7M stock compensation net of tax.","Declared regular quarterly cash dividend of $0.17/share, payable May 30, 2025 to holders of record May 20.","Q2 2025 guidance: revenue $19.7-19.9M; GAAP EPS $0.37-0.40; non-GAAP EPS $0.41-0.44.","Reaffirms FY 2025 guidance: revenue $78-82M; GAAP EPS $1.55-1.65; non-GAAP EPS $1.71-1.81."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":19510637.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171256,"accession_number":"0001558370-25-000907","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED Q4 revenue $19.4M (+11% YoY); raises quarterly dividend to $0.17/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue record $19.4M (+11% YoY); GAAP EPS $0.40, non-GAAP EPS $0.44.","Full year 2024 revenue $73.2M (+12% YoY); GAAP EPS $1.50, non-GAAP EPS $1.66.","Quarterly dividend increased 13% to $0.17/share from $0.15; payable March 5, 2025.","FY2025 guidance: revenue $78-82M, GAAP EPS $1.55-1.65, non-GAAP EPS $1.71-1.81.","New Orlando facility on track for mid-2025 completion; ~$5.5M capex remaining in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":73242121.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171255,"accession_number":"0001558370-25-000117","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.","Full-year 2024 revenue ~$73.1M-$73.3M vs $65.6M in 2023, YoY growth 11-12%.","Orders booked in Q4 exceeded shipments, building robust backlog for 2025.","CEO Roger Susi cites increasing demand expected to continue through 2025.","Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":73242121.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188231,"accession_number":"0001558370-24-014005","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.","Raises FY 2024 GAAP EPS guidance to $1.49-$1.52 (from $1.37-$1.47) and Non-GAAP to $1.64-$1.67 (from $1.52-$1.62).","Declares regular quarterly cash dividend of $0.15/share, payable Nov 25, 2024 to holders of record Nov 15, 2024.","Q3 cash flow from operations was $9.1M, vs $1.4M in prior year; new Orlando facility capex ~$9M remaining.","Q4 2024 guidance: revenue $18.8M-$19.2M, GAAP EPS $0.39-$0.42, Non-GAAP EPS $0.42-$0.45."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":53852954.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204719,"accession_number":"0001558370-24-010533","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.","GAAP diluted EPS $0.38; non-GAAP diluted EPS $0.42 vs $0.36 in Q2 2023.","Q3 2024 guidance: revenue $18.0-18.2M, GAAP EPS $0.34-0.37.","FY 2024 reaffirmed: revenue $72-74M, GAAP EPS $1.37-1.47.","Declares quarterly dividend $0.15/share payable Aug 30, record Aug 20."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":35526995.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221572,"accession_number":"0001558370-24-009354","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iradimed stockholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Roger Susi (9,119,299 for), Monty Allen (9,709,115), Anthony Vuoto (10,720,742), Hilda Scharen-Guivel (10,741,229), James Hawkins (8,771,444).","Ratification of RSM US LLP as independent auditor for FY2024: 11,609,434 for, 13,044 against, 2,073 abstentions.","Advisory vote on executive compensation approved: 10,684,897 for, 197,682 against, 32,812 abstentions; 709,160 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221571,"accession_number":"0001558370-24-008988","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"IRADIMED uplists to Nasdaq Global Market, trading starts June 14, 2024 under IRMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq approved transfer from Capital Market to Global Market, effective June 14, 2024.","Ticker remains 'IRMD'; no stockholder action required.","CEO Roger Susi highlights continued growth and enhanced visibility from higher listing standards.","Nasdaq Global Market includes ~1,450 companies with stricter financial and governance requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221570,"accession_number":"0001558370-24-008847","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IRADIMED extends headquarters lease by one year to May 2025 in related-party deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended to May 31, 2025, with possible month-to-month holdover through Nov 2025.","Monthly base rent set at $34,133, adjusted annually for CPI; company pays insurance and maintenance.","Landlord SUSI, LLC is controlled by CEO/President/Chairman Roger Susi, making this a related-party transaction.","Company waived its second five-year renewal option under the original lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221569,"accession_number":"0001558370-24-006460","cik":1325618,"company_name":"IRADIMED CORP","ticker":"IRMD","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.","GAAP diluted EPS $0.32, non-GAAP $0.36; net income $4.1M, +21.4%.","Declared regular quarterly dividend of $0.15/share payable May 30, 2024 to holders of record May 20.","Q2 2024 guidance: revenue $17.6-17.8M, GAAP EPS $0.33-0.36, non-GAAP $0.36-0.39.","FY 2024 guidance reiterated: revenue $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":17598119.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1158398610.5842772,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}